According to our study, for the first time, we found that the daily administration of YC-1102 reduced the liver/body weight ratio and plasma liver injury parameters such as ALT and AST levels in mice with NASH (Figure 1). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.